Evelien Smits

Prof. Evelien Smits

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
SASébastien Anguille
Sébastien Anguille
ESEvelien Smits
Evelien Smits
ELEva Lion
Eva Lion
VTViggo Van Tendeloo
Viggo Van Tendeloo
ZBZwi N Berneman
Zwi N Berneman

1 February 2020 in Seminars in Cancer Biology
Verified
Journal Article
Open access
YVYannick Verhoeven
Yannick Verhoeven
STSam Tilborghs
Sam Tilborghs
JJJulie Jacobs
Julie Jacobs
JWJorrit De Waele
Jorrit De Waele
DQDelphine Quatannens
Delphine Quatannens
Peter Van DamPeter Van Dam
Peter Van Dam
The Signal Transducer and Activator of Transcription (STAT) family of proteins consists of transcription factors that play a complex and essential role in the regulation of physiologic cell processes, such as proliferation, differentiation, apoptosis and angiogenesis, and serves to organize the epigenetic landscape of immune cells. To date, seven STAT genes have been identified in the human genome; STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. They all account for diverse effects in response to extracellular signaling proteins, mainly by altering gene transcription in the effector cells. Members of the STAT family have been implicated in human cancer development, progression, metastasis, survival and resistance to treatment. Particularly STAT3 and STAT5 are of interest in cancer biology. They are currently considered as oncogenes, but their signaling is embedded into a complex and delicate balance between different (counteracting) transcription factors, and thus, in some contexts they can have a tumor suppressive role. Assessing STAT signaling mutations as well as screening for aberrant STAT pathway activation may have a role to predict sensitivity to immunotherapy and targeted STAT inhibition. In the present comprehensive review of the literature, we discuss in-depth the role of each STAT family member in cancer, assemble cutting-edge information on the use of these molecules as potential biomarkers and targets for treatment, and address why their clinical implementation is controversy.

24 July 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
HAHeleen H. Van Acker
Heleen H. Van Acker
ACAnna Capsomidis
Anna Capsomidis
ESEvelien Smits
Evelien Smits
VTViggo F. Van Tendeloo
Viggo F. Van Tendeloo
Over the past years, the phenotypic and functional boundaries distinguishing the main cell subsets of the immune system have become increasingly blurred. In this respect, CD56 (also known as NCAM) is a very good example. CD56 is the archetypal phenotypic marker of natural killers cells, but can actually be expressed by many more immune cells, including alpha beta (αβ) T cells, gamma delta (γδ) T cells, dendritic cells and monocytes. Common to all these CD56-expressing cell types are strong immunostimulatory effector functions, including T helper 1 cytokine production and an efficient cytotoxic capacity. Interestingly, both numerical and functional deficiencies and phenotypic alterations of the CD56+ immune cell fraction have been reported in patients with various infectious, autoimmune or malignant diseases. In this review, we will discuss our current knowledge on the expression and function of CD56 in the hematopoietic system, both in health and disease.

14 July 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
VTViggo Van Tendeloo
Viggo Van Tendeloo
AVAnn Van de Velde
Ann Van de Velde
ADAnn Van Driessche
Ann Van Driessche
NCNathalie Cools
Nathalie Cools
SASébastien Anguille
Sébastien Anguille
ZBZwi N. Berneman
Zwi N. Berneman
Active immunization using tumor antigen-loaded dendritic cells holds promise for the adjuvant treatment of cancer to eradicate or control residual disease, but so far, most dendritic cell trials have been performed in end-stage cancer patients with high tumor loads. Here, in a phase I/II trial, we investigated the effect of autologous dendritic cell vaccination in 10 patients with acute myeloid leukemia (AML). The Wilms’ tumor 1 protein (WT1), a nearly universal tumor antigen, was chosen as an immunotherapeutic target because of its established role in leukemogenesis and superior immunogenic characteristics. Two patients in partial remission after chemotherapy were brought into complete remission after intradermal administration of full-length WT1 mRNA-electroporated dendritic cells. In these two patients and three other patients who were in complete remission, the AML-associated tumor marker returned to normal after dendritic cell vaccination, compatible with the induction of molecular remission. Clinical responses were correlated with vaccine-associated increases in WT1-specific CD8 + T cell frequencies, as detected by peptide/HLA-A*0201 tetramer staining, and elevated levels of activated natural killer cells postvaccination. Furthermore, vaccinated patients showed increased levels of WT1-specific IFN-γ–producing CD8 + T cells and features of general immune activation. These data support the further development of vaccination with WT1 mRNA-loaded dendritic cells as a postremission treatment to prevent full relapse in AML patients.

28 January 2019 in Advanced Science
Verified
Journal Article
Open access
PDF file
Abraham LinAbraham Lin
Abraham Lin
YGYury Gorbanev
Yury Gorbanev
JBJoey De Backer
Joey De Backer
JLJinthe Van Loenhout
Jinthe Van Loenhout
WBWilma Van Boxem
Wilma Van Boxem
Annemie  BogaertsAnnemie Bogaerts
Annemie Bogaerts
Breakthroughs in cancer immunotherapies have demonstrated considerable success, though not without limitations. Non‐thermal plasma (NTP) for cancer therapy has been emerging as a potential adjuvant treatment via induction of immunogenic cell death (ICD). Cancer cells undergoing ICD stimulate a patient's immune system to mount an anticancer response. While promising, the underlying mechanisms of NTP‐induced ICD must be closely examined. Here, the interaction between non‐thermal plasma and cancerous cells is studied. The short‐lived reactive oxygen and nitrogen species (e.g., hydroxyl radicals, atomic oxygen, nitric oxide) produced by plasma are the main effectors that elicit ICD in melanoma while, surprisingly, persistent species do not. This is demonstrated in vitro using a dielectric barrier discharge plasma system and is validated in a vaccination assay in vivo. Plasma generation of reactive species appears to be dictated by the total energy. Collectively, this work provides fundamental insight into plasma interactions with biological material. Furthermore, it lays the foundation for future development of NTP systems for clinical translation. The addition of plasma systems into the existing arsenal of cancer therapies opens the possibility for new combination strategies for safer and more robust control of cancer.

1 November 2015 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
JJJulie Jacobs
Julie Jacobs
VDV. Deschoolmeester
V. Deschoolmeester
KZK. Zwaenepoel
K. Zwaenepoel
CRC. Rolfo
C. Rolfo
KSK. Silence
K. Silence
PPP. Pauwels
P. Pauwels